# mtPCDI: a machine learning-based prognostic model for prostate cancer recurrence

## TL;DR

This study creates a machine learning model called mtPCDI to predict prostate cancer recurrence based on mitochondrial and cell death gene interactions.

## Contribution

The novel contribution is the development of mtPCDI, a prognostic index combining mitochondrial function and programmed cell death for prostate cancer.

## Key findings

- mtPCDI effectively predicts prostate cancer recurrence prognosis.
- Lower mtPCDI scores correlate with higher immune activity and better outcomes.
- The model supports personalized risk assessment and treatment decisions.

## Abstract

This research seeks to formulate a prognostic model for forecasting prostate cancer recurrence by examining the interaction between mitochondrial function and programmed cell death (PCD).

The research involved analyzing four gene expression datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) using univariate Cox regression. These analyses identified genes linked with mitochondrial function and PCD that correlate with recurrence prognosis. Various machine learning algorithms were then employed to construct an optimal predictive model.

A key outcome was the creation of a mitochondrial-related programmed cell death index (mtPCDI), which effectively predicts the prognosis of prostate cancer patients. It was observed that individuals with lower mtPCDI exhibited higher immune activity, correlating with better recurrence outcomes.

The study demonstrates that mtPCDI can be used for personalized risk assessment and therapeutic decision-making, highlighting its clinical significance and providing insights into the biological processes affecting prostate cancer recurrence.